To develop a common data model for patients with EOC that can be analysed locally according to a pre-defined plan agreed by all centres
• To describe OS from initial diagnosis in patients diagnosed with EOC and in various sub-populations • To describe the baseline sociodemographic and clinical characteristics of patients diagnosed with EOC, including tumour stage, morphology and grade, and molecular and genetic phenotype including BRCA status. • To describe surgical treatment patterns including the use of exploratory/diagnostic laparoscopy, the timing and extent of ‘debulking’ (or cytoreduction) surgery (primary, interval or delayed procedure) including rates of lymphadenectomy, bowel resection and stoma formation or primary anastomosis. • To describe non-surgical management including the use of all types of systemic anti-cancer therapy (SACT) i.e. chemotherapy, monoclonal antibodies, targeted therapies (especially the PARP inhibitors), hormone therapy, immunotherapy and radiotherapy. • To describe duration of treatment and time to next treatment (TTNT) i.e. treatment free interval (TFI) between each treatment programme
Institut de Cancérologie de l'Ouest
Patients with a primary diagnosis of EOC, based on ICD10 codes C56 (ovary), C57 (fallopian tube) and C48 (primary peritoneal) and relevant morphology codes (see Annex 1) or based on imaging results and CA125 levels
6.e) RGPD le traitement est nécessaire à l'exécution d'une mission d'intérêt public
IQVIA
Conservation pendant 2 ans après la valorisation (publication/article, thèse, présentation orale, poster, autre) des résultats de la recherche. Puis archivage avec un accès restreint aux personnes intervenant dans la recherche, pendant une durée limitée de 3 ans (5ans au total post publication)